PhD position in microfluidic drug discovery and protein interaction mapping

During the past couple of years, the Laboratory of Biomedical Microfluidics (LBMM) at the École Polytechnique Fédérale de Lausanne (EPFL) have established powerful microfluidic platforms for antibody and drug discovery, which also led to the successful establishment of a startup company and an international consortium for personalized cancer therapy (www.veraxa.de and www.besttherapyforme.com). 

We are now inviting applications for PhD positions with a particular focus on antibody and drug discovery. The aim of the proposed PhD project is to perform highly multiplexed protein-interaction studies, also involving DNA-encoded libraries technology (DELT). Ideal candidates have prior experience in display technologies (e.g. mammalian, yeast or phage), antibody engineering and discovery, or profound knowledge in DELT. Throughout the project, successful candidates will have the chance to pick up new skills in microfluidics, next generation sequencing (optionally at the single cell level) and multiplexed data analysis.

The group is very interdisciplinary and includes people with various backgrounds, including biologists, bioinformaticians, engineers and programmers. However, prior knowledge in microfluidics is not mandatory for joining!

Work rate: 100%

Duration of studies: 48 months

The earliest starting date: April 1, 2022

For additional information and application submission, please email Prof. Christoph Merten ([email protected])